Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma von Jansen, Y.J.L., Rozeman, E.A., Mason, R., Goldinger, S.M., Geukes Foppen, M.H., Hoejberg, L., Schmidt, H., van Thienen, J.V., Haanen, J.B.A.G., Tiainen, L., Svane, I.M., Mäkelä, S., Seremet, T., Arance, A., Dummer, R., Bastholt, L., Nyakas, M., Straume, O., Menzies, A.M., Long, G.V., Atkinson, V., Blank, C.U., Neyns, B.

Volltext

Vemurafenib for BRAF V600 mutated advanced melanoma: Results of treatment beyond progression von Scholtens, A, Geukes Foppen, M.H, Blank, C.U, van Thienen, J.V, van Tinteren, H, Haanen, J.B

Volltext

MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial von Rohaan, M.W., Gomez-Eerland, R., van den Berg, J.H., Geukes Foppen, M.H., van Zon, M., Raud, B., Jedema, I., Scheij, S., de Boer, R., Bakker, N.A.M., van den Broek, D., Pronk, L.M., Grijpink-Ongering, L.G., Sari, A., Kessels, R., van den Haak, M., Mallo, H.A., Karger, M., van de Wiel, B.A., Zuur, C.L., Duinkerken, C.W., Lalezari, F., van Thienen, J.V., Wilgenhof, S., Blank, C.U., Beijnen, J.H., Nuijen, B., Schumacher, T.N., Haanen, J.B.A.G.

Volltext

Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials von Versluis, J.M., Menzies, A.M., Sikorska, K., Rozeman, E.A., Saw, R.P.M., van Houdt, W.J., Eriksson, H., Klop, W.M.C., Ch’ng, S., van Thienen, J.V., Mallo, H., Gonzalez, M., Torres Acosta, A., Grijpink-Ongering, L.G., van der Wal, A., Bruining, A., van de Wiel, B.A., Scolyer, R.A., Haanen, J.B.A.G., Schumacher, T.N., van Akkooi, A.C.J., Long, G.V., Blank, C.U.

Volltext

Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma von Rawson, R.V., Adhikari, C., Bierman, C., Lo, S.N., Shklovskaya, E., Rozeman, E.A., Menzies, A.M., van Akkooi, A.C.J., Shannon, K.F., Gonzalez, M., Guminski, A.D., Tetzlaff, M.T., Stretch, J.R., Eriksson, H., van Thienen, J.V., Wouters, M.W., Haanen, J.B.A.G., Klop, W.M.C., Zuur, C.L., van Houdt, W.J., Nieweg, O.E., Ch'ng, S., Rizos, H., Saw, R.P.M., Spillane, A.J., Wilmott, J.S., Blank, C.U., Long, G.V., van de Wiel, B.A., Scolyer, R.A.

Volltext

Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma von Geukes Foppen, M.H., Brandsma, D., Blank, C.U., van Thienen, J.V., Haanen, J.B., Boogerd, W.

Volltext

Outcome of patients with synchronous metastatic renal cell carcinoma treated with nivolumab and ipilimumab and the primary tumour in place von Jurascheck, L., Fransen Van De Putte, E., Van Den Brink, L., Van Der Mijn, J.C., Wilgenhof, S., Van Thienen, J.V., Haanen, J.B.A.G., Boleti, E., Powles, T., Zondervan, P.J., Graafland, N.M., Bex, A.

Volltext

A0838 - Outcome of patients with synchronous metastatic renal cell carcinoma treated with nivolumab and ipilimumab and the primary tumour in place von Jurascheck, L., Fransen Van De Putte, E., Van Den Brink, L., Van Der Mijn, J.C., Wilgenhof, S., Van Thienen, J.V., Haanen, J.B.A.G., Boleti, E., Powles, T., Zondervan, P.J., Graafland, N.M., Bex, A.

Volltext

PO-1483 Hypofractionated radiotherapy combined with targeted therapy or immunotherapy: Dutch survey von van Aken, E.S., van der Linden, Y.M., Marijnen, C.A., van Thienen, J.V., de Langen, A.J., de Jong, M.C.

Volltext

Deferred cytoreductive nephrectomy following response to ipilimumab/nivolumab, is there potential for a treatment-free interval? von Fransen van de Putte, E.E., Van Den Brink, L., Mansour, M., Van Der Mijn, J.C., Wilgenhof, S., Van Thienen, J.V., Haanen, J.B.A., Boleti, E., Powles, T., Zondervan, P.J., Graafland, N.M., Bex, A.

Volltext

A0327 - Deferred cytoreductive nephrectomy following response to ipilimumab/nivolumab, is there potential for a treatment-free interval? von Fransen van de Putte, E.E., Van Den Brink, L., Mansour, M., Van Der Mijn, J.C., Wilgenhof, S., Van Thienen, J.V., Haanen, J.B.A., Boleti, E., Powles, T., Zondervan, P.J., Graafland, N.M., Bex, A.

Volltext

737P Synchronous metastatic renal cell carcinoma (mRCC) treated with nivolumab and ipilimumab (N+I) and the primary tumour (PT) in place von Meerveld-Eggink, A., Graafland, N., Wilgenhof, S., van Thienen, J.V., Grant, M., Szabados, B.E., Abu-Ghanem, Y., Boleti, E., Blank, C.U., Haanen, J.B.A.G., Powles, T.B., Bex, A.

Volltext

567P Exposure-response analyses of dabrafenib and trametinib in melanoma patients von Groenland, S.L., Janssen, J.M., Nijenhuis, C., de Vries, N., Rosing, H., Wilgenhof, S., van Thienen, J.V., Haanen, J.B.A.G., Blank, C.U., Beijnen, J., Huitema, A., Steeghs, N.

Volltext

Increase in S100B and LDH as early outcome predictors for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma von Rozeman, E.A., Moritz, R., Wilgenhof, S., van Thienen, J.V., Haanen, J B A G, van den Heuvel, M., Blank, C.U., Van Rossum, H.

Volltext

1356P - Increase in S100B and LDH as early outcome predictors for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma von Rozeman, E.A., Moritz, R., Wilgenhof, S., van Thienen, J.V., Haanen, J B A G, van den Heuvel, M., Blank, C.U., Van Rossum, H.

Volltext

Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience von Meerveld-Eggink, A., Rozeman, E.A., Lalezari, F., van Thienen, J.V., Haanen, J.B.A.G., Blank, C.U.

Volltext

1097P 4-year relapse-free survival (RFS), overall survival (OS) and long-term toxicity of (neo)adjuvant ipilimumab (IPI) + nivolumab (NIVO) in macroscopic stage III melanoma: OpACI... von Versluis, J.M., Reijers, I.L.M., Rozeman, E.A., Sikorska, K., van Houdt, W.J., van Thienen, J.V., Adriaansz, S.A., Mallo, H., van Tinteren, H., van de Wiel, B.A., Grijpink-Ongering, L.G., Bruining, A., Haanen, J.B.A.G., van Akkooi, A.C.J., Schumacher, T.N., Blank, C.U.

Volltext

Is routine skin examination in metastatic melanoma patients treated with immuno‐ or targeted therapy necessary? von Huis in't Veld, E.A., van Seventer, I.C., van Teeseling, L., van Thienen, J.V., Crijns, M.B.

Volltext

Switch to checkpoint inhibition (CPI) after targeted therapy (TT) at time of progression or during ongoing response: A retrospective analysis of patients with advanced BRAF mutated... von Reijers, I.L.M., Rozeman, E.A., Mallo, H., Uyterlinde, W., Adriaansz, S., Lijnsvelt, J., Wilgenhof, S., van Thienen, J.V., Haanen, J.B.A.G., Blank, C.U.

Volltext

Neurological benefit of BRAF-inhibition and MEK-inhibition in patients with brain metastases from BRAF-mutated melanoma von Foppen, M. Geukes, Boogerd, W., Blank, C., Haanen, J.B.A.G., van Thienen, J.V., Brandsma, D.

Volltext